sNDA and sBLA Drug Pipeline Report – 2H 2025

IPD Analytics has released its sNDA and sBLA Drug Pipeline Report – 2H 2025, featuring analyses on 17 key drugs poised for potential FDA approval for new or expanded indications over the next 6 months. For each product in the report, our experts include a clinical summary, expected place in therapy, and comparative pricing insights.

Complete with a timeline of upcoming PDUFA dates for select drugs with sBLA and sNDA submissions, the report helps payers track these approvals and proactively prepare for P&T committee reviews, update coverage policies, and assess any necessary adjustments to management strategies.

Content on this site is proprietary to IPD Analytics. By receiving this sample you are agreeing to refrain from any unauthorized use, including uploading or inputting into AI tools or large language models for any purpose, is strictly prohibited.